NF-kappa B as a therapeutic target in multiple myeloma. - Wikidata - wikimedia - TriplyDB

NF-kappa B as a therapeutic target in multiple myeloma.

NF-kappa B as a therapeutic target in multiple myeloma.

http://www.wikidata.org/entity/Q34521393

about

The Synthetic Compound Norcantharidin Induced Apoptosis in Mantle Cell Lymphoma In Vivo and In Vitro through the PI3K-Akt-NF- κ B Signaling Pathway Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Antioxidants potentiate American ginseng-induced killing of colorectal cancer cells Treatment of light chain deposition disease with bortezomib and dexamethasone Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy Novel agents in the treatment of multiple myeloma: a review about the future Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis Concise review: Leukemia stem cells in personalized medicine Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Trial Watch: Proteasomal inhibitors for anticancer therapy Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma Targeting NF-kappaB in Waldenstrom macroglobulinemia Ubiquitination and degradation of the inhibitors of NF-kappaB microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia Drug inhibition profile prediction for NFκB pathway in multiple myeloma Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster.Identification of consensus genes and key regulatory elements in 5-fluorouracil resistance in gastric and colon cancer.Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Targeting the UPS as therapy in multiple myeloma.The UPS: a promising target for breast cancer treatment.A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits".Recent advances in antimultiple myeloma drug development.An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo.Integrated microarray and multiplex cytokine analyses of Kaposi's Sarcoma Associated Herpesvirus viral FLICE Inhibitory Protein K13 affected genes and cytokines in human blood vascular endothelial cells.Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy.Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.

P2860

Q21284854-2CE0C6E0-AD37-4CAD-88D1-C03943A532CC Q24570128-030F7F65-2A4E-4CE1-9894-FAF60A7E777F Q24605861-E51172AC-F864-4B49-B6A4-6659F1FCAB85 Q24646272-28B09B31-9556-405D-BFAB-0974170385EE Q24658325-1837BC28-A04F-404D-95FF-6F6C76CF2E1A Q24669938-1C3E9114-C057-428F-B591-2E95F6FA5480 Q24670297-1D40F8A8-766C-488E-8BD4-36D462B3F2E6 Q24814325-9468BBA7-CF61-4243-B334-6AEE445C6CC8 Q26745924-60B39EE1-5DA6-478B-9C9D-D93F1A14E575 Q26822486-95C3119E-3A65-49E3-B918-4A1392714718 Q26995268-9BE84962-04D7-45BB-B1D6-84BF8E254992 Q27307731-73910DEC-9586-467F-A913-CF9F4C97BD4C Q28067148-C1AEE10E-65E3-4C75-B4D4-7F6C23ADC1EF Q28082335-777753DE-971C-4E0C-A505-DAF2A2382E8B Q28082910-0EBA1F51-FE37-456D-A33D-43FC5DA44FB2 Q28271286-97FAA3E6-0B85-4A5D-B409-A3A106AB1041 Q28272373-6774BA3D-7CEF-47DB-B7A4-AF76C5D1D3AE Q28274205-1C4BAD3B-1EF5-42BF-A840-FE7D92E22A0E Q28303661-3EE43A47-1BF1-4F97-AC4E-9F3307E8270A Q28477374-680ECF1C-CFE1-449E-B00D-88AEE45D667C Q28478936-33EB4B0E-9C2A-4910-B6CC-3C9F22B22DC2 Q28533426-015027FC-BACD-496C-8D09-7D2B57AF98E0 Q28534151-E6DD1279-5250-4208-9755-F3610AFC2C1D Q30424831-35C508EA-3D70-4153-BCD2-9BE1D165BA67 Q30952817-0547EBF4-9EE6-40D5-AF0B-8D1ABA292450 Q31028788-7BC3B870-D49E-469D-9E1A-8D8EFBAE4B70 Q33226589-3AE9A909-C805-4C89-8083-F35F513E48C3 Q33258202-0E11150B-F8A3-4774-A831-C363AFBCFC3D Q33298577-EB581B32-C2E9-432A-99CA-47DC08BB5B9B Q33367821-BCB54329-1086-46EB-871D-3BD8A73AEDFC Q33384287-85FCE85F-F77F-4444-89ED-4721C207041F Q33384289-DBACFC9F-D209-4E1D-B7DE-63FADAC525C1 Q33414478-E50EA13C-C2AF-4FB3-839B-9A235104D332 Q33416297-E89BA110-9FA8-4B94-BC28-139B25A79FF9 Q33418098-F6D2A204-EA10-4752-9FD2-DAC1A5152D73 Q33426864-7B9712C7-CDCD-4EFB-ABC0-B19EE43C4CCF Q33491306-684A77D1-5ABA-4328-AF9E-B19E4AE6BF39 Q33585280-FC82239C-191A-40F4-BF3D-94FF87D0AA5F Q33633401-F27599F9-47E4-479F-AD87-9F4C066948EF Q33701777-7CFA5A86-F475-48D5-954C-36E13C0A3935

P2860

NF-kappa B as a therapeutic target in multiple myeloma.

http://www.wikidata.org/entity/Q34521393

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

NF-kappa B as a therapeutic target in multiple myeloma.

@ast

NF-kappa B as a therapeutic target in multiple myeloma.

@en

NF-kappa B as a therapeutic target in multiple myeloma.

@nl

type

label

NF-kappa B as a therapeutic target in multiple myeloma.

@ast

NF-kappa B as a therapeutic target in multiple myeloma.

@en

NF-kappa B as a therapeutic target in multiple myeloma.

@nl

prefLabel

NF-kappa B as a therapeutic target in multiple myeloma.

@ast

NF-kappa B as a therapeutic target in multiple myeloma.

@en

NF-kappa B as a therapeutic target in multiple myeloma.

@nl

P1433

Q34521393-AD08D403-5EB2-44AB-9D6C-C0A4F1CC5A29

P1476

Q34521393-8F5B66A8-17EB-446A-B002-DE77D759A5CF

P2093

Q34521393-27F5127F-1DF7-48C6-8D4A-643A0810146F

Q34521393-36C68E18-AC24-4633-8A5C-8AC167AB0400

Q34521393-49EB7D83-D861-43ED-8720-F89792442A07

Q34521393-642B1699-8ACA-4ECC-8935-FFB3370972D9

Q34521393-69762C58-9222-45FA-91BD-0E211204EBBA

Q34521393-6AA2D7D3-65A9-4528-BFC3-4C44C4DFC657

Q34521393-6DE54CA1-2FA1-403C-A062-6DAA2307DAAE

Q34521393-96AEC18B-E858-450F-B022-2130205E7DAF

Q34521393-AA4FC0C0-DD3D-43F8-BBE6-C54486B34239

Q34521393-E4B8456C-5EAF-4ACF-BC05-7359C3E58687

P304

Q34521393-3C1522D8-9033-4A62-A8A0-6F5EF78C08F7

P31

Q34521393-0DFCE0C0-6DEF-4B27-89F1-B361941B6CFB

P356

Q34521393-D884BCC1-F87D-4002-AB0B-528A32D4B540

P407

Q34521393-E95B81B2-746B-465F-9612-C7C3EBBBEAE5

P433

Q34521393-0071B528-AC22-4A8E-B306-D173F64C40B1

P478

Q34521393-E1BBE6CC-9D23-4D10-9C26-AFD23F747857

P50

Q34521393-B25EE102-8030-49BA-BEA9-935A3BFAE8A0

Q34521393-F32E171E-B9E3-4B1D-8CDF-75955788EE9B

P577

Q34521393-80B0ABF0-C05F-42C1-9D02-81F873214F60

P698

Q34521393-216AFF98-B7A5-4018-AF75-4A1B4FB1384D

P921

Q34521393-0F8EE686-94C6-4DA1-9424-D395E11465B4

P356

P1433

Journal of Biological Chemistry

P1476

NF-kappa B as a therapeutic target in multiple myeloma.

@en

P2093

Alfredo Castro

http://www.w3.org/2001/XMLSchema#string

Constantine Mitsiades

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Julian Adams

http://www.w3.org/2001/XMLSchema#string

Lenny Dang

http://www.w3.org/2001/XMLSchema#string

Nicholas Mitsiades

http://www.w3.org/2001/XMLSchema#string

Nikhil Munshi

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

Toshiaki Hayashi

http://www.w3.org/2001/XMLSchema#string

Vito Palombella

http://www.w3.org/2001/XMLSchema#string

P304

16639-16647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M200360200

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

277

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2002-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11872748

http://www.w3.org/2001/XMLSchema#string

P921